Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

TriptorelinvsLeuprolide

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.

Hormone SupportHormone Support

At a Glance

Quick
comparison

Dose Range

Triptorelin

0.1 mg–22.5 mg mg

Leuprolide

3.75 mg–45 mg monthly or 3-month injections (depending on formulation)

Frequency

Triptorelin

Once daily

Leuprolide

Once daily

Administration

Triptorelin

Intramuscular injection

Leuprolide

Subcutaneous injection (daily)

Cycle Length

Triptorelin

Ongoing/indefinite

Leuprolide

Ongoing/indefinite

Onset Speed

Triptorelin

Moderate (1-2 weeks)

Leuprolide

Moderate (1-2 weeks)

Evidence Level

Triptorelin

Strong human trials (Phase 3 or FDA approved)

Leuprolide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Triptorelin
Leuprolide

Hormone Regulation

Triptorelin94%
Leuprolide0%

Cancer Management

Triptorelin90%
Leuprolide94%

Endometriosis Relief

Triptorelin87%
Leuprolide0%

Endometriosis & Fibroid Relief

Triptorelin0%
Leuprolide90%

Hormone Control

Triptorelin0%
Leuprolide87%

Technical Data

Compound
specifications

Triptorelin

Molecular Formula

C64H82N18O13

Molecular Weight

1311.4 g/mol

Half-Life

2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)

Bioavailability

~100% (intramuscular/subcutaneous injection)

CAS Number

57773-63-4

Leuprolide

Molecular Formula

C59H84N16O12

Molecular Weight

1209.4 g/mol

Half-Life

Approximately 2-6 hours (varies by route of administration)

Bioavailability

~95% (subcutaneous injection)

CAS Number

74381-53-6

Applications

Best
suited for

Triptorelin

Managing advanced prostate cancer when combined with other treatments

Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving severe endometriosis pain and symptoms

Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying puberty development in children with early sexual maturation

Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Leuprolide

Managing advanced or metastatic prostate cancer

Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Controlling severe endometriosis pain

Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Treating symptomatic uterine fibroids

Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying early puberty in children

Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Triptorelin

Leuprolide

Common

  • Hot flashes (very common in men)
  • Decreased libido and erectile dysfunction
  • Injection site pain or swelling
  • Nausea
  • Fatigue
  • Mood changes or depression
  • Joint or muscle pain
  • Headaches
  • Dizziness
  • Thinning hair
  • Decreased bone density (osteoporosis with long-term use)
  • QT prolongation (rare but serious cardiac effect)
  • Tumor flare (temporary worsening of cancer symptoms in first weeks)
  • Severe allergic reactions
  • Spinal cord compression risk in men with metastatic disease

Serious

  • Severe allergic reaction

Research Status

Safety
& evidence

Triptorelin

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

  • xPregnancy (can affect fetal development)
  • xUndiagnosed vaginal bleeding
  • xKnown hypersensitivity to GnRH agonists
  • xSevere untreated depression
  • xActive spinal cord compression in prostate cancer (requires urgent decompression)

Leuprolide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient.

Contraindications

  • xPregnancy or breastfeeding (teratogenic)
  • xUndiagnosed vaginal bleeding
  • xActive bone metastases with spinal cord compression (increased fracture risk)
  • xAllergy to GnRH agonists or components
  • xSevere cardiovascular disease with QT prolongation risk

Decision Guide

Which is
right for you?

Choose Triptorelin if...

  • Managing advanced prostate cancer when combined with other treatments
  • Relieving severe endometriosis pain and symptoms
  • Delaying puberty development in children with early sexual maturation

Choose Leuprolide if...

  • Managing advanced or metastatic prostate cancer
  • Controlling severe endometriosis pain
  • Treating symptomatic uterine fibroids
  • Delaying early puberty in children